T2 AM 'Omic' Technologies: Current and Future Application to Environmental Toxicology (Part 1)
Tuesday, 15 November 2005: 8:00 AM - 11:40 AM in Ballroom 2

(GOO-1117-573373) Toxicogenomics in the identification of biomarkers of nephrotoxicity for multiple species.

Goodsaid, F¹, ¹ Genomics, Office of Clinical Pharmacology and Biopharmaceutics, CDER, US Food and Drug Administration, Rockville, Maryland, USA

ABSTRACT- Results from toxicogenomic studies provide a common lexicon in the search for biomarkers of toxicity across multiple species. One of the best examples of this application of toxicogenomics has been the identification of genomic biomarkers of nephrotoxicity. Genomic and proteomic biomarkers for nephrotoxicity have been identified in rats, monkeys and humans on the basis of results from several studies in these species. The value of these biomarkers is clear for each species in which they have been identified, but the common language provided by toxicogenomic markers has also helped understand similarities and differences in toxicity between species. These studies have also shown a close relationship between the detection of transcriptomic and proteomic versions of these markers, leading to their potential use in clinical applications.

Key words: toxicogenomics, nephrotoxicity, kidney toxicity